

|   |       |
|---|-------|
| CERTIFICATION OF FACSIMILE TRANSMISSION   |       |
| I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below. |       |
| <hr/>   |       |
| Type or print name of person signing certification  |       |
| <hr/>   | <hr/> |
| Signature   | Date  |

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Konstantinos GAVARDINAS      Group Art Unit: 1626  
Serial No.: 10/576,761      Examiner: R. Anderson  
Application Date: April 21, 2006      Conf No.: 3926  
For:: TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR  
MODULATORS  
  
Docket No.: X-16534

**RESPONSE TO NOTICE TO COMPLY**

Commissioner for Patents  
Mail Stop Missing Parts  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the "Notice To Comply" accompanying the Office Action dated 29 December 2009 noting that the application does not contain: (1) as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c); and (2) a copy of the "Sequence Listing" in computer readable form as required by 37 CFR 1.821(e).

Enclosed herewith are: 1) a copy of the Notice and 2) An amendment specifically directing entry of the Sequence Listing into the application and 3) a Sequence Listing in paper (.pdf) and computer readable form (ST25.txt) and (4) a Sequence Listing Statement as required by 37 CFR 1.821 (e), 1.821 (f), 1.821 (g).

Respectfully submitted,

/Alexander Wilson/  
Alexander Wilson  
Attorney for Applicants  
Registration No. 45,782  
Phone: 317-277-0190

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
March 29, 2010

|                         |                                 |                                   |  |
|-------------------------|---------------------------------|-----------------------------------|--|
| <b>Notice to Comply</b> | Application No.<br>10576761     | Applicant(s)<br>GAVARDINAS ET AL. |  |
|                         | Examiner<br>REBECCA L. ANDERSON | Art Unit<br>1626                  |  |

  

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951  
 For CRF Submission Help, call (571) 272-2510  
 PatentIn Software Program Support  
 Technical Assistance. 1-866-217-9197 or 703-305-3028 or 571-272-6845  
 PatentIn Software is Available At [www.USPTO.gov](http://www.USPTO.gov)

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

|  |  |
|--|--|
| /Rebecca L. Anderson/<br>Primary Examiner, Art Unit 1626 |  |
|--|--|